BR112012013823A2 - "formulação farmacêutica parenteral em suspensão, de liberação prolongada" - Google Patents

"formulação farmacêutica parenteral em suspensão, de liberação prolongada"

Info

Publication number
BR112012013823A2
BR112012013823A2 BR112012013823-5A BR112012013823A BR112012013823A2 BR 112012013823 A2 BR112012013823 A2 BR 112012013823A2 BR 112012013823 A BR112012013823 A BR 112012013823A BR 112012013823 A2 BR112012013823 A2 BR 112012013823A2
Authority
BR
Brazil
Prior art keywords
progesterone
particles
estradiol
pharmaceutical formulation
release parenteral
Prior art date
Application number
BR112012013823-5A
Other languages
English (en)
Other versions
BR112012013823B1 (pt
Inventor
Ángeles Uribe Juan
Claude Savoir Vilboeuf John
Original Assignee
Techsphere, S.A. De C.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44167908&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012013823(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Techsphere, S.A. De C.V. filed Critical Techsphere, S.A. De C.V.
Publication of BR112012013823A2 publication Critical patent/BR112012013823A2/pt
Publication of BR112012013823B1 publication Critical patent/BR112012013823B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

"formulação farmacêutica parenteral em suspensão, de liberação prolongada". formulação ou composição farmacêutica parenteral, em suspensão, tendo liberação prolongada, contendo partículas em suspensão de estradiol e progesterona para reposição hormonal em mamíferos fêmea em dosagem baixa e ultra baixa; a formulação consiste em uma suspensão injetável compreendendo partículas de estradiol, partículas de progesterona, um agente surfactante, um agente isosmótico, um agente espessante e um ou mais conservantes, em que o estradiol está em partículas de tamanho entre 1 e 100 microns, e a progesterona está em partículas de tamanho entre 1 e 100 microns, para sua aplicação nas formas farmacêuticas parenteral, intramuscular, subcutânea ou intradérmica.
BR112012013823-5A 2009-12-15 2010-12-14 formulação farmacêutica parenteral em suspensão, de liberação prolongada BR112012013823B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
MX2009013768 2009-12-15
MXMX/A/2009/013768 2009-12-15
PCT/MX2010/000154 WO2011074931A2 (es) 2009-12-15 2010-12-14 Formulación farmacéutica parenteral en suspensión, de liberación sostenida, en dosis baja y ultra baja, en terapia hormonal en el síndrome climatérico

Publications (2)

Publication Number Publication Date
BR112012013823A2 true BR112012013823A2 (pt) 2018-07-31
BR112012013823B1 BR112012013823B1 (pt) 2021-05-25

Family

ID=44167908

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012013823-5A BR112012013823B1 (pt) 2009-12-15 2010-12-14 formulação farmacêutica parenteral em suspensão, de liberação prolongada

Country Status (34)

Country Link
EP (1) EP2520301B2 (pt)
JP (1) JP5900925B2 (pt)
KR (1) KR101758407B1 (pt)
CN (1) CN102655867B (pt)
AR (1) AR079453A1 (pt)
AU (1) AU2010330982B2 (pt)
BR (1) BR112012013823B1 (pt)
CA (1) CA2781999C (pt)
CL (1) CL2012001516A1 (pt)
CO (1) CO6551723A2 (pt)
CY (1) CY1119169T1 (pt)
DK (1) DK2520301T4 (pt)
EC (1) ECSP12011934A (pt)
ES (1) ES2629204T5 (pt)
HK (1) HK1170431A1 (pt)
HR (1) HRP20170962T4 (pt)
HU (1) HUE035223T2 (pt)
IL (1) IL220422A (pt)
LT (1) LT2520301T (pt)
MA (1) MA33808B1 (pt)
MX (1) MX2012006604A (pt)
MY (1) MY163619A (pt)
NZ (1) NZ600539A (pt)
PE (1) PE20130015A1 (pt)
PL (1) PL2520301T5 (pt)
PT (1) PT2520301T (pt)
RS (1) RS56142B2 (pt)
RU (1) RU2582272C2 (pt)
SG (1) SG181723A1 (pt)
SI (2) SI2520301T2 (pt)
UA (1) UA108865C2 (pt)
UY (1) UY33103A (pt)
WO (1) WO2011074931A2 (pt)
ZA (1) ZA201203992B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY33103A (es) * 2009-12-15 2011-07-29 Techsphere S A De C V Formulacion farmaceutica parenteral en suspension, de liberacion sostenida, en dosis baja y ultra baja, en terapia hormonal en el sindrome climaterico
WO2017105512A1 (en) 2015-12-18 2017-06-22 Proinvet Innovations S.A. Formulations and methods for controlling the reproductive cycle and ovulation

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3733407A (en) 1971-08-25 1973-05-15 Syntex Corp Menopause treatment
US4425339A (en) 1981-04-09 1984-01-10 Syntex (U.S.A.) Inc. Treatment of menopausal symptoms
US4900734A (en) 1987-08-27 1990-02-13 Maxson Wayne S Novel pharmaceutical composition containing estradiol and progesterone for oral administration
US4945103A (en) 1989-01-17 1990-07-31 Michael Cohen Method of treating pre-menstrual syndrome
FR2663224B1 (fr) 1990-06-14 1995-01-20 Applicationes Farmaceuticas Sa Forme galenique parenterale.
FR2663223B1 (fr) * 1990-06-14 1994-12-02 Af Aplicaciones Far Lab Forme galenique parenterale.
US6613757B1 (en) * 1994-09-22 2003-09-02 Board Of Regents, The University Of Texas System Combination of prostacyclin with an estrogen or progestin for the prevention and treatment of atherosclerotic vascular disease including preeclampsia and for the treatment of hypertension, and for hormone replacement therapy
SE9403389D0 (sv) * 1994-10-06 1994-10-06 Astra Ab Pharmaceutical composition containing derivattves of sex hormones
US5514382A (en) 1994-10-17 1996-05-07 Sultenfuss; Sherry Daily vitamin and mineral supplement for women
FR2747042B1 (fr) * 1996-04-05 1998-06-05 Besins Iscovesco Lab Medicament a base de progesterone et d'oestradiol
US6287693B1 (en) 1998-02-25 2001-09-11 John Claude Savoir Stable shaped particles of crystalline organic compounds
FR2777784B1 (fr) * 1998-04-27 2004-03-19 Arepa Composition pharmaceutique a base d'estrogene et de progesterone
WO2000021511A2 (en) * 1998-10-09 2000-04-20 Pharmacia & Upjohn Company Subcutaneous medroxyprogesterone acetate for treatment of menopause and endometriosis
EP1187618A1 (en) * 1999-06-04 2002-03-20 The General Hospital Corporation Pharmaceutical formulations for treating postmenopausal and perimenopausal women, and their use
US6495534B2 (en) * 2000-05-15 2002-12-17 Pharmacia & Upjohn Spa Stabilized aqueous suspensions for parenteral use
AU2004246870B2 (en) * 2003-06-13 2009-07-23 Skendi Finance Ltd Slow release estradiol-progesterone formulation for contraception and hormone replacement therapy
TW200726473A (en) * 2005-06-28 2007-07-16 Wyeth Corp Compositions and methods for treatment of cycle-related symptoms
UY33103A (es) * 2009-12-15 2011-07-29 Techsphere S A De C V Formulacion farmaceutica parenteral en suspension, de liberacion sostenida, en dosis baja y ultra baja, en terapia hormonal en el sindrome climaterico

Also Published As

Publication number Publication date
KR20120114269A (ko) 2012-10-16
ECSP12011934A (es) 2012-07-31
EP2520301A2 (en) 2012-11-07
ES2629204T3 (es) 2017-08-07
MX2012006604A (es) 2012-08-17
NZ600539A (en) 2014-10-31
CA2781999C (en) 2018-10-23
MY163619A (en) 2017-10-13
CO6551723A2 (es) 2012-10-31
JP2013513658A (ja) 2013-04-22
WO2011074931A2 (es) 2011-06-23
IL220422A (en) 2017-01-31
AU2010330982A1 (en) 2012-07-05
RS56142B1 (sr) 2017-10-31
CA2781999A1 (en) 2011-06-23
CN102655867A (zh) 2012-09-05
PE20130015A1 (es) 2013-01-30
ZA201203992B (en) 2013-02-27
KR101758407B1 (ko) 2017-07-14
DK2520301T4 (da) 2021-06-07
RU2012126501A (ru) 2014-01-27
PL2520301T3 (pl) 2017-10-31
AU2010330982B2 (en) 2015-05-21
RS56142B2 (sr) 2021-07-30
HUE035223T2 (hu) 2018-05-02
PT2520301T (pt) 2017-06-30
MA33808B1 (fr) 2012-12-03
IL220422A0 (en) 2012-08-30
BR112012013823B1 (pt) 2021-05-25
EP2520301A4 (en) 2013-10-23
CY1119169T1 (el) 2018-02-14
LT2520301T (lt) 2017-07-25
SG181723A1 (en) 2012-07-30
EP2520301B1 (en) 2017-05-10
HRP20170962T4 (hr) 2021-07-09
WO2011074931A3 (es) 2011-09-22
AR079453A1 (es) 2012-01-25
HRP20170962T1 (hr) 2017-09-22
PL2520301T5 (pl) 2021-07-05
JP5900925B2 (ja) 2016-04-06
CL2012001516A1 (es) 2012-12-21
DK2520301T3 (en) 2017-07-17
RU2582272C2 (ru) 2016-04-20
SI2520301T1 (sl) 2017-07-31
UY33103A (es) 2011-07-29
SI2520301T2 (sl) 2021-08-31
CN102655867B (zh) 2015-05-27
ES2629204T5 (es) 2021-11-02
EP2520301B2 (en) 2021-03-03
UA108865C2 (uk) 2015-06-25
HK1170431A1 (en) 2013-03-01

Similar Documents

Publication Publication Date Title
ES2531646T3 (es) Composiciones de emulsión farmacéuticas con bajo contenido de aceite que comprenden progestágeno
BR112018015824A2 (pt) composições para higiene pessoal
BR112017022021A2 (pt) aplicação de agente anticaspa solúvel em tensoativo
CL2016001547A1 (es) Composiciones para el cuidado oral
BR112015023321A2 (pt) dispersões submicrômetras substancialmente livres de surfactante e alimento com as mesmas
CL2007003730A1 (es) Nanoemulsion que comprende a) componente acuoso y b) un vehiculo con i) 0,1-15% de un componente lipofilico, ii) un tensoactivo y iii) un alcohol c3-c5; composicion que la comprende opcionalmente con un agente activo; proceso de preparacion de la nanoemulsion y de la composicion; kit; y uso para diagnosticar enfermedades dermicas y proliferativas, y tratar enfermedades virales, dermicas y proliferativas.
BR112014032497A2 (pt) sistema de descarga de propante e um recipiente para uso em tal sistema de descarga de propante
AR072933A1 (es) Sistema de administracion de drogas con contenido de progestina
BR112017004418A2 (pt) óxido que contém zircônio e cério de elevada porosidade
BR112012033391A2 (pt) kit contraceptivo, método contraceptivo para uma paciente do sexo feminino necessitando do mesmo e composição farmacêutica compreendendo drospirenova.
BR112014019730A8 (pt) Sistema tensoativo estruturado aquoso e composição de cuidado pessoal
BR112015028499A2 (pt) Peptídeo para induzir apoptose específica de mastócito e uso do mesmo
MX2021003510A (es) Formulaciones mezcladas.
CL2011003327A1 (es) Composicion farmaceutica que comprende finafloxacina y un agente antiinflamatorio; uso en el tratamiento de infecciones oftalmicas, oticas o nasales.
BR112015001640A2 (pt) formulações e métodos de produção de formulações para uso em evacuação colônica
BR112013022431A2 (pt) derivado de polissacarídeo, forma de dosagem, processo para preparar uma forma de dosagem e uso de um derivado de polissacarídeo
BR112015014853A2 (pt) Formulação farmacêutica, formulação farmacêutica liofilizada, uso de uma formulação farmacêutica e artigo de manufatura
NZ598518A (en) Concentrated polypeptide formulations with reduced viscosity
CL2012001835A1 (es) Uso de una formulacion que comprende un agente viscogenico y moxifloxacina para preparar un medicamento util para tratar el oido medio.
BRPI1011071B8 (pt) uso de um heptapeptídeo para estimular a função genital, sexual ou reprodutiva em um mamífero
BR112012013823A2 (pt) "formulação farmacêutica parenteral em suspensão, de liberação prolongada"
IN2013MU01331A (pt)
BR112017025043A2 (pt) formulação para cuidado dos cabelos
AR065703A1 (es) Uso de una micro - emulsion acuosa para la preparacion de una formulacion para el tratamiento de enfermedades adiposas y dicha micro - emulsion
BR112015032449A2 (pt) composição e processo em particular para o cuidado, a limpeza e/ou o condicionamento das matérias queratínicas

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/12/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF